{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "To analyse the impact of the pathogenic mutations on parkin function, we analysed the E3 ligase activity of parkin mutants in an ubiquitination assay... A western blot analysis revealed that in comparison to wild-type parkin significantly less ubiquitinated proteins present in cell lysates after expression of the R42P... indicating that these mutants show a reduced E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay used in the study directly measures the E3 ligase activity of parkin, which is central to the disease mechanism (loss of function) defined in Step 1. This class of assay is applicable and relevant to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells were transiently co-transfected with Flag-tagged ubiquitin and wt-parkin or parkin mutants... As a control for equal amounts of proteins loaded, the amount of Hsp70 was determined... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and compares it against mutant forms. Additionally, it explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "A western blot analysis revealed that in comparison to wild-type parkin significantly less ubiquitinated proteins present in cell lysates after expression of the R42P and W453Stop parkin mutant, indicating that these mutants show a reduced E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The study uses W453Stop, a known pathogenic variant, as a control alongside R42P in the ubiquitination assay. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No explicit statistical tests or OddsPath calculations are provided for the ubiquitination assay results comparing R42P to wild-type parkin.",
          "judgment": "No",
          "reasoning": "The paper does not provide specific statistical analyses or OddsPath values for the functional impact of R42P on E3 ligase activity. Only qualitative comparisons (e.g., 'significantly less ubiquitinated proteins') are mentioned without quantitative metrics or p-values.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and one additional pathogenic variant control (W453Stop) in the ubiquitination assay for comparison with R42P.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to R42P is less than 11 (only wild-type and W453Stop are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R42P is rated as PS3_supporting due to the use of a relevant ubiquitination assay demonstrating reduced E3 ligase activity, inclusion of basic controls and replicates, and a known pathogenic variant control (W453Stop). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "W",
          "alt": "Stop",
          "position": "453"
        },
        "variant_string_id": "PARK2 W453Stop"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "To analyse the impact of the pathogenic mutations on parkin function, we analysed the E3 ligase activity of parkin mutants in an ubiquitination assay... A western blot analysis revealed that in comparison to wild-type parkin significantly less ubiquitinated proteins present in cell lysates after expression of the... W453Stop parkin mutant, indicating that these mutants show a reduced E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay used in the study directly measures the E3 ligase activity of parkin, which is central to the disease mechanism (loss of function) defined in Step 1. This class of assay is applicable and relevant to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells were transiently co-transfected with Flag-tagged ubiquitin and wt-parkin or parkin mutants... As a control for equal amounts of proteins loaded, the amount of Hsp70 was determined... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and compares it against mutant forms. Additionally, it explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "A western blot analysis revealed that in comparison to wild-type parkin significantly less ubiquitinated proteins present in cell lysates after expression of the R42P and W453Stop parkin mutant, indicating that these mutants show a reduced E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The study uses R42P, another known pathogenic variant, as a control alongside W453Stop in the ubiquitination assay. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No explicit statistical tests or OddsPath calculations are provided for the ubiquitination assay results comparing W453Stop to wild-type parkin.",
          "judgment": "No",
          "reasoning": "The paper does not provide specific statistical analyses or OddsPath values for the functional impact of W453Stop on E3 ligase activity. Only qualitative comparisons (e.g., 'significantly less ubiquitinated proteins') are mentioned without quantitative metrics or p-values.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and one additional pathogenic variant control (R42P) in the ubiquitination assay for comparison with W453Stop.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to W453Stop is less than 11 (only wild-type and R42P are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 W453Stop is rated as PS3_supporting due to the use of a relevant ubiquitination assay demonstrating reduced E3 ligase activity, inclusion of basic controls and replicates, and a known pathogenic variant control (R42P). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "Q",
          "position": "33"
        },
        "variant_string_id": "PARK2 R33Q"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling of parkin indicated that an increased degradation was responsible for reduced protein levels... Twenty-four hours after synthesis, more than 70% of wild-type full-length parkin was still present; however, the amount of full-length R33Q was reduced.",
          "judgment": "Yes",
          "reasoning": "The metabolic labelling and pulse/chase assay used to assess protein stability indirectly relates to the loss of parkin function by demonstrating reduced protein levels due to degradation, which impacts the availability of functional parkin. This class of assay is applicable to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells transiently expressing wt-parkin (wt) or the indicated parkin mutants were metabolically labelled... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling compared wild-type parkin with mutants including R33Q, R42P, K48A, and V56E.",
          "judgment": "Yes",
          "reasoning": "The study includes multiple variants (R42P, K48A, V56E) alongside R33Q in the metabolic labelling assay, with R42P noted as a known pathogenic variant. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative analysis of the experiment... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments and set as 100%.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data on protein stability over time, it does not include specific statistical tests or OddsPath calculations to correlate the reduced stability of R33Q with pathogenicity likelihood.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and multiple variant controls (R42P, K48A, V56E) in the metabolic labelling assay for comparison with R33Q.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to R33Q is less than 11 (only wild-type and a few other mutants are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R33Q is rated as PS3_supporting due to the use of a relevant metabolic labelling assay demonstrating reduced protein stability, inclusion of basic controls and replicates, and known pathogenic variant controls (e.g., R42P). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "K",
          "alt": "A",
          "position": "48"
        },
        "variant_string_id": "PARK2 K48A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling of parkin indicated that an increased degradation was responsible for reduced protein levels... Twenty-four hours after synthesis, more than 70% of wild-type full-length parkin was still present; however, the amount of full-length K48A was reduced.",
          "judgment": "Yes",
          "reasoning": "The metabolic labelling and pulse/chase assay used to assess protein stability indirectly relates to the loss of parkin function by demonstrating reduced protein levels due to degradation, which impacts the availability of functional parkin. This class of assay is applicable to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells transiently expressing wt-parkin (wt) or the indicated parkin mutants were metabolically labelled... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling compared wild-type parkin with mutants including R33Q, R42P, K48A, and V56E.",
          "judgment": "Yes",
          "reasoning": "The study includes multiple variants (R33Q, R42P, V56E) alongside K48A in the metabolic labelling assay, with R42P noted as a known pathogenic variant. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative analysis of the experiment... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments and set as 100%.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data on protein stability over time, it does not include specific statistical tests or OddsPath calculations to correlate the reduced stability of K48A with pathogenicity likelihood.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and multiple variant controls (R33Q, R42P, V56E) in the metabolic labelling assay for comparison with K48A.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to K48A is less than 11 (only wild-type and a few other mutants are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 K48A is rated as PS3_supporting due to the use of a relevant metabolic labelling assay demonstrating reduced protein stability, inclusion of basic controls and replicates, and known pathogenic variant controls (e.g., R42P). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "V",
          "alt": "E",
          "position": "56"
        },
        "variant_string_id": "PARK2 V56E"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling of parkin indicated that an increased degradation was responsible for reduced protein levels... Twenty-four hours after synthesis, more than 70% of wild-type full-length parkin was still present; however, the amount of full-length V56E was reduced.",
          "judgment": "Yes",
          "reasoning": "The metabolic labelling and pulse/chase assay used to assess protein stability indirectly relates to the loss of parkin function by demonstrating reduced protein levels due to degradation, which impacts the availability of functional parkin. This class of assay is applicable to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells transiently expressing wt-parkin (wt) or the indicated parkin mutants were metabolically labelled... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Pulse/chase experiments after metabolic labelling compared wild-type parkin with mutants including R33Q, R42P, K48A, and V56E.",
          "judgment": "Yes",
          "reasoning": "The study includes multiple variants (R33Q, R42P, K48A) alongside V56E in the metabolic labelling assay, with R42P noted as a known pathogenic variant. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative analysis of the experiment... The relative amount of parkin present in the detergent-soluble fraction after the pulse was determined from at least three independent experiments and set as 100%.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data on protein stability over time, it does not include specific statistical tests or OddsPath calculations to correlate the reduced stability of V56E with pathogenicity likelihood.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and multiple variant controls (R33Q, R42P, K48A) in the metabolic labelling assay for comparison with V56E.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to V56E is less than 11 (only wild-type and a few other mutants are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 V56E is rated as PS3_supporting due to the use of a relevant metabolic labelling assay demonstrating reduced protein stability, inclusion of basic controls and replicates, and known pathogenic variant controls (e.g., R42P). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "E",
          "alt": "Stop",
          "position": "409"
        },
        "variant_string_id": "PARK2 E409Stop"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In contrast to wild-type parkin, the two C-terminal deletion mutants W453Stop and E409Stop were not found in the vesicle fraction... indicating that C-terminal deletions induce rapid misfolding of parkin and the formation of large protein aggregates.",
          "judgment": "Yes",
          "reasoning": "The detergent solubility and sucrose gradient assays used to assess protein misfolding and aggregation, along with membrane association assays, are relevant as they demonstrate a loss of normal parkin localization and conformation, which likely impacts its E3 ligase function. This class of assay is applicable to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells were transiently transfected with wt-parkin (wt) or the indicated parkin mutants... Quantitative analysis of wt-parkin and the C-terminal deletion mutants... determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "In contrast to wild-type parkin, the two C-terminal deletion mutants W453Stop and E409Stop were not found in the vesicle fraction... similarly to the W453Stop mutant.",
          "judgment": "Yes",
          "reasoning": "The study includes W453Stop, a known pathogenic variant, as a control alongside E409Stop in the misfolding and localization assays. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative analysis revealed that about 90% of wild-type parkin is in a detergent-soluble conformation, whereas more than 80% of the C-terminal deletion mutants is found in the pellet fraction.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data on the proportion of soluble versus insoluble protein, it does not include specific statistical tests or OddsPath calculations to correlate the misfolding of E409Stop with pathogenicity likelihood.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and multiple variant controls (W453Stop, Q311Stop, K211Stop) in the misfolding and localization assays for comparison with E409Stop.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to E409Stop is less than 11 (only wild-type and a few other mutants are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 E409Stop is rated as PS3_supporting due to the use of relevant assays demonstrating misfolding and loss of membrane association, inclusion of basic controls and replicates, and a known pathogenic variant control (W453Stop). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "Q",
          "alt": "Stop",
          "position": "311"
        },
        "variant_string_id": "PARK2 Q311Stop"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The autosomal recessive mode of inheritance implies that loss of parkin function plays a significant role in the pathogenesis of ARPD. Functional studies established that some mutations in the parkin gene interfere with the E3 ligase activity of parkin.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of parkin function, specifically related to its E3 ligase activity, which is critical in the pathogenesis of autosomal recessive Parkinson's disease (ARPD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In contrast to wild-type parkin... E409Stop and Q311Stop were found in scattered aggregates... indicating that C-terminal deletions induce rapid misfolding of parkin and the formation of large protein aggregates.",
          "judgment": "Yes",
          "reasoning": "The detergent solubility and immunofluorescence assays used to assess protein misfolding and aggregation are relevant as they demonstrate a loss of normal parkin localization and conformation, which likely impacts its E3 ligase function. This class of assay is applicable to ARPD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "N2a cells were transiently transfected with wt-parkin (wt) or the indicated parkin mutants... Quantitative analysis of wt-parkin and the C-terminal deletion mutants... determined from at least three independent experiments.",
          "judgment": "Yes",
          "reasoning": "The study includes wild-type parkin as a normal control and explicitly mentions performing experiments in at least three independent replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "In contrast to wild-type parkin... E409Stop and Q311Stop were found in scattered aggregates, similarly to the W453Stop mutant.",
          "judgment": "Yes",
          "reasoning": "The study includes W453Stop and E409Stop, known pathogenic variants, as controls alongside Q311Stop in the misfolding and localization assays. This satisfies the criterion of using known pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Quantitative analysis revealed that about 90% of wild-type parkin is in a detergent-soluble conformation, whereas more than 80% of the C-terminal deletion mutants is found in the pellet fraction.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data on the proportion of soluble versus insoluble protein, it does not include specific statistical tests or OddsPath calculations to correlate the misfolding of Q311Stop with pathogenicity likelihood.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes wild-type parkin and multiple variant controls (W453Stop, E409Stop, K211Stop) in the misfolding and localization assays for comparison with Q311Stop.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the assay relevant to Q311Stop is less than 11 (only wild-type and a few other mutants are mentioned). As per the flowchart, this limits the evidence strength to supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 Q311Stop is rated as PS3_supporting due to the use of relevant assays demonstrating misfolding and aggregation, inclusion of basic controls and replicates, and known pathogenic variant controls (e.g., W453Stop, E409Stop). However, the lack of statistical analyses or OddsPath calculation and the limited number of variant controls (less than 11) restrict the strength to supporting."
    }
  ]
}